Radius Health Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
12,303.00
105,276.00
473,339.00
332,494.00
253,333.00
237,021
Total Accounts Receivable
-
-
-
-
4,441.00
16,758
Inventories
-
-
-
-
4,366.00
6,210
Other Current Assets
334.00
2,057.00
6,969.00
2,315.00
7,366.00
15,044
Total Current Assets
12,637.00
107,333.00
480,308.00
334,809.00
269,506.00
275,033
Net Property, Plant & Equipment
76.00
842.00
1,897.00
4,922.00
6,195.00
4,003
Total Investments and Advances
-
-
-
-
176,978.00
-
Intangible Assets
-
-
-
-
8,180.00
7,382
Other Assets
45.00
242.00
260.00
551.00
799.00
544
Total Assets
12,758.00
108,417.00
482,465.00
340,282.00
461,658.00
286,962
ST Debt & Current Portion LT Debt
13,005.00
-
-
-
-
Accounts Payable
300.00
-
-
-
3,915.00
Other Current Liabilities
22,007.00
20,559.00
21,180.00
32,725.00
49,512.00
Total Current Liabilities
35,312.00
20,559.00
21,180.00
32,725.00
53,427.00
Long-Term Debt
-
24,394.00
-
-
166,006.00
Other Liabilities
1,945.00
-
-
379.00
189.00
Total Liabilities
37,257.00
44,953.00
21,180.00
33,104.00
219,622.00
Common Equity (Total)
277,301.00
63,464.00
461,285.00
307,178.00
242,036.00
Total Shareholders' Equity
24,499.00
63,464.00
461,285.00
307,178.00
242,036.00
Total Equity
24,499.00
63,464.00
461,285.00
307,178.00
242,036.00
Liabilities & Shareholders' Equity
12,758.00
108,417.00
482,465.00
340,282.00
461,658.00
Preferred Stock (Carrying Value)
252,802.00
-
-
-
-

About Radius Health

View Profile
Address
950 Winter Street
Waltham Massachusetts 02451
United States
Employees -
Website http://www.radiuspharm.com
Updated 07/08/2019
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The firm's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women.